Home | Site map | Contact us
Change type size: A | A
Press releases
For more information or background, contact our press officers:
Maria Patey
or Richard Anderson
DeFacto Communications Ltd
Tel: +44 (0)20 7861 3838
Press releases:
Background:
 |
|
|
Latest press release:
EDEN
BIODESIGN AND STEALTHYX THERAPEUTICS LTD SIGN DEAL TO DEVELOP ENHANCED
TREATMENT FOR RHEUMATOID ARTHRITIS
Liverpool, UK; 6 March 2008: Eden Biodesign Ltd, one
of the UK’s leading contract bio manufacturers and Stealthyx Therapeutics
Ltd, a London based biotechnology company, announced today that they have
entered into an agreement to develop and produce Stealthyx’s lead
therapeutic candidate that the company is evaluating for treatment of
a range of inflammatory diseases including rheumatoid arthritis.
The product will incorporate Stealthyx Therapeutics’ proprietary
Prothyx technology that has been developed by Professor Yuti Chernajovsky
at St. Bartholomews Hospital and The London, Queen Mary's School of Medicine
and Dentistry, University of London. Prothyx harnesses the properties
of a naturally occurring peptide to confer stability and disease targeting
biological therapeutics resulting in improved efficacy and lower side
effect profile.
Dr Crawford Brown, CEO, Eden Biodesign commented: “We are delighted
to work with Stealthyx Therapeutics on the development of this new class
of biologics. We have the expertise in product development and cGMP manufacturing
infrastructure that is necessary to rapidly deliver such novel therapeutics
to the market “.
Professor Yuti Chernajovsky said: “We are very pleased to be working
with Eden Biodesign on the development of this innovative product. By
accessing Eden’s state-of-the art facility in Liverpool and their
demonstrated experience and track record in the successful development
of complex biopharmaceuticals we will undoubtedly accelerate the clinical
development of Stealthyx Therapeutics’ products and their transition
from research laboratories to patients”.
This project has been funded by the National Biomanufacturing Centre (NBC)
Access Fund administered by the Northwest Regional Development Agency
(NWDA).
Dr Linda Magee, NWDA Biotechnology Sector Director & Head of Bionow,
commented: “the NBC was set up by the Agency and its funding partners
to help UK SMEs and research groups translate product ideas to the clinic
- the Stealthyx project is a very good example of how the NBC, and Eden
as its operators, are helping to develop the biopharmaceutical product
pipeline for UK plc”.
Ends
